Should children be on GLP-1 weight loss drugs? - Dr. Ralph DeFronzo

Peter Attia Asks the Question That Makes Everyone Uncomfortable

Should we be prescribing GLP-1 weight loss drugs to children? Dr. Peter Attia, a physician known for his work on longevity and metabolic health, tackles this question head-on in a conversation that is both medically grounded and emotionally charged. Childhood obesity has tripled in the United States since the 1970s. About 20% of American children and adolescents are now classified as obese, and many of them are developing conditions that used to be considered adult diseases: type 2 diabetes, fatty liver disease, high blood pressure, and sleep apnea. The old playbook of "eat less and move more" has failed this population on a population level, and the question of pharmaceutical intervention has become impossible to avoid.

The guest in this conversation, Dr. Ralph DeFronzo, is one of the most published researchers in diabetes and metabolic disease. He has spent decades studying insulin resistance and the mechanisms underlying obesity. His perspective carries weight in the medical community because it is grounded in physiology rather than opinion, and because he is willing to engage with uncomfortable questions that other researchers avoid.

The conversation starts with a basic observation: we already give children medications for chronic conditions. Kids with asthma take inhaled corticosteroids. Kids with ADHD take stimulant medications. Kids with type 1 diabetes take insulin. In each of these cases, the medical community accepted pharmaceutical intervention for children because the disease risk outweighed the medication risk. The question for GLP-1 drugs is whether childhood obesity meets the same bar, and the answer depends heavily on how you define the risks on both sides of the equation.

The Case for Early Intervention

Dr. DeFronzo makes a physiological argument that is hard to dismiss. Obesity in childhood creates metabolic damage that compounds over time. The longer someone is obese, the more insulin resistance develops, the more fat accumulates in the liver, the more inflammation becomes chronic, and the harder it becomes to reverse the metabolic dysfunction through lifestyle changes alone. A 12-year-old who has been obese for four years is not in the same metabolic position as a 30-year-old who has been obese for two years. The child's body has been developing and growing in an abnormal metabolic environment, and that shapes organ development, hormonal signaling, and even brain development in ways that may not be fully reversible later.

There is also the psychological component. Childhood obesity is associated with higher rates of depression, anxiety, social isolation, and bullying. These psychological effects can persist into adulthood independent of whether the weight itself is eventually lost. The argument for early intervention is that preventing years of metabolic damage and psychological harm is better than waiting until the damage is done and then trying to repair it.

The clinical trial data for GLP-1 drugs in adolescents is limited but encouraging. The STEP TEENS trial tested semaglutide in adolescents aged 12 to 17 with obesity and found an average weight reduction of about 16% after 68 weeks, compared to a slight gain in the placebo group. The side effect profile was similar to what is seen in adults: primarily gastrointestinal symptoms that were manageable for most participants. There were no unexpected safety signals specific to the adolescent population in that trial.

The FDA approved semaglutide (Wegovy) for adolescents aged 12 and older in 2023, and tirzepatide (Zepbound) received a similar indication in 2024. So the regulatory decision has already been made for teenagers. The more controversial question that Attia and DeFronzo discuss is whether these drugs should be used in even younger children, and what the threshold for intervention should be.

The Case for Caution

The counterarguments are serious and deserve honest consideration. GLP-1 drugs have only been available for a few years in their current widespread use. We do not have 10-year or 20-year safety data on these medications in adults, let alone in children whose bodies are still developing. The long-term effects on bone density, muscle development, puberty timing, brain development, and growth trajectory are simply unknown at this point.

Dr. Attia raises the concern about lean mass loss. In adults, up to 40% of weight lost on GLP-1 drugs can come from lean tissue rather than fat. In children, who are actively building muscle and bone, this concern is amplified. Growing bodies need adequate protein, calories, and hormonal signals to develop properly. A drug that suppresses appetite significantly in a child could potentially interfere with growth and development in ways that do not become apparent for years.

There is also the question of medicalization and the message it sends. Critics argue that prescribing weight loss drugs to children normalizes pharmaceutical solutions for what is fundamentally an environmental and societal problem. Children are obese in large part because they live in an environment designed to make them obese: processed food is cheap and everywhere, physical activity has been engineered out of daily life, and screen time has replaced active play. Giving a child a drug to counteract that environment without changing the environment itself is treating a symptom while leaving the cause untouched.

Dr. DeFronzo acknowledges this critique but pushes back on it practically. Yes, the environment should change. Yes, we should improve school lunches, increase physical education, reduce junk food marketing to children, and make healthy food more accessible. But those changes happen slowly, at the policy level, over years and decades. The child who is obese today cannot wait for society to fix itself. They are accumulating metabolic damage right now, and they deserve treatment right now, even if the treatment is imperfect and the root causes remain unaddressed.

What the Guidelines Currently Say

The American Academy of Pediatrics (AAP) updated its clinical practice guidelines for childhood obesity in 2023, and the update was significant. For the first time, the AAP recommended that pharmacotherapy be considered for children aged 12 and older with obesity (BMI at or above the 95th percentile) when lifestyle interventions alone have not achieved adequate improvement. The guideline also recommends discussing bariatric surgery for adolescents with severe obesity (BMI at or above 120% of the 95th percentile), which was a notable shift from previous guidance that was much more conservative about surgical intervention in minors.

The AAP guidelines emphasize that medication should be used alongside behavioral and lifestyle interventions, not instead of them. The drug is meant to be part of a full treatment plan that includes dietary counseling, physical activity support, psychological assessment, and family-based behavioral change. Prescribing a GLP-1 drug to a child without addressing the broader lifestyle context would be bad medicine regardless of your position on pediatric pharmacotherapy.

Dr. DeFronzo agrees with the thorough approach but makes the point that lifestyle interventions alone have a very low success rate in children with severe obesity. Studies consistently show that behavioral programs produce modest weight loss (typically 5 to 7% of body weight) that is often not sustained beyond a year. For a child with a BMI above the 99th percentile, a 5% reduction is clinically insignificant and does not meaningfully change their metabolic trajectory. Adding pharmacotherapy to the mix does not replace the lifestyle work. It amplifies it.

The Muscle Loss and Growth Question

Attia circles back to this repeatedly because it is the concern he finds most pressing. Children and adolescents are in an anabolic growth phase. They are building bone, building muscle, developing their endocrine systems, and maturing neurologically. All of these processes require adequate nutrition, adequate calories, and appropriate hormonal signaling. A drug that suppresses appetite by 30 to 50%, which is what GLP-1 drugs do in many patients, could create a caloric deficit that impairs these processes even if it produces desirable weight loss.

The available data from the STEP TEENS trial is reassuring on a 68-week timescale: no significant effects on growth velocity or bone density markers were observed. But 68 weeks is a short window when you are talking about child development. The more important questions involve what happens over 3, 5, or 10 years of use, and those answers do not exist yet. Dr. DeFronzo acknowledges the gap but argues that the known harms of persistent childhood obesity (type 2 diabetes by age 15, fatty liver by age 12, cardiovascular disease risk factors well before adulthood) are not theoretical. They are happening right now in millions of children, and the risk of inaction is not zero.

Where This Leaves Parents and Pediatricians

Attia and DeFronzo do not arrive at a tidy conclusion, which is honest. The decision to prescribe a GLP-1 drug to a child should be individualized, made with a pediatric obesity specialist, and based on a careful assessment of the child's specific metabolic status, the severity of their obesity, the failure of previous lifestyle interventions, and the family's ability to support a full treatment approach.

If you are a parent of a child with obesity, start with a pediatrician who takes the condition seriously and does not dismiss it as something the child will "grow out of." Most children with obesity become adults with obesity. Get a full metabolic workup including fasting glucose, insulin, lipids, liver enzymes, and ideally a liver ultrasound. Implement the lifestyle changes that are within your control: reduce ultra-processed food at home, increase family physical activity, limit screen time, and address any psychological factors contributing to overeating.

If lifestyle changes over 3 to 6 months are not producing meaningful improvement, discuss pharmacotherapy with your child's doctor. This is not a failure. It is a recognition that biology is powerful and that some children need additional tools to overcome a metabolic environment that is working against them. The conversation is uncomfortable, but avoiding it does not make the problem go away. It just delays the consequences.